144 related articles for article (PubMed ID: 16227989)
1. T cells targeted against a single minor histocompatibility antigen can cure solid tumors.
Meunier MC; Delisle JS; Bergeron J; Rineau V; Baron C; Perreault C
Nat Med; 2005 Nov; 11(11):1222-9. PubMed ID: 16227989
[TBL] [Abstract][Full Text] [Related]
2. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease.
Fontaine P; Roy-Proulx G; Knafo L; Baron C; Roy DC; Perreault C
Nat Med; 2001 Jul; 7(7):789-94. PubMed ID: 11433342
[TBL] [Abstract][Full Text] [Related]
3. Adoptive cancer immunotherapy: discovering the best targets.
Perreault C; Brochu S
J Mol Med (Berl); 2002 Apr; 80(4):212-8. PubMed ID: 11976730
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of cancer through targeting of minor histocompatibility antigens.
Hambach L; Goulmy E
Curr Opin Immunol; 2005 Apr; 17(2):202-10. PubMed ID: 15766682
[TBL] [Abstract][Full Text] [Related]
5. A continuous infusion of a minor histocompatibility antigen-immunodominant peptide induces a delay of male skin graft rejection.
Sireci G; Barera A; Macaluso P; Di Sano C; Bonanno CT; Pio La Manna M; Di Liberto D; Dieli F; Salerno A
Immunobiology; 2009; 214(8):703-11. PubMed ID: 19249121
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
Ohashi M; Kobayashi A; Hara H; Miura Y; Yoshida K; Kushida M; Ikarashi Y; Mandai M; Kitajima M; Yoshida T; Aoki K
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2208-15. PubMed ID: 16609036
[TBL] [Abstract][Full Text] [Related]
7. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and immunogenetic analysis of an immunodominant peptide (B6dom1) encoded by the classical H7 minor histocompatibility locus.
Eden PA; Christianson GJ; Fontaine P; Wettstein PJ; Perreault C; Roopenian DC
J Immunol; 1999 Apr; 162(8):4502-10. PubMed ID: 10201988
[TBL] [Abstract][Full Text] [Related]
9. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
[TBL] [Abstract][Full Text] [Related]
10. Vaccine-instructed intratumoral IFN-γ enables regression of autochthonous mouse prostate cancer in allogeneic T-cell transplantation.
Hess Michelini R; Manzo T; Sturmheit T; Basso V; Rocchi M; Freschi M; Listopad J; Blankenstein T; Bellone M; Mondino A
Cancer Res; 2013 Aug; 73(15):4641-52. PubMed ID: 23749644
[TBL] [Abstract][Full Text] [Related]
11. Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application.
Griffioen M; van Egmond HM; Barnby-Porritt H; van der Hoorn MA; Hagedoorn RS; Kester MG; Schwabe N; Willemze R; Falkenburg JH; Heemskerk MH
Haematologica; 2008 Oct; 93(10):1535-43. PubMed ID: 18768532
[TBL] [Abstract][Full Text] [Related]
12. Minor histocompatibility antigens: targets for tumour therapy and transplant tolerance.
Spierings E
Int J Immunogenet; 2008 Aug; 35(4-5):363-6. PubMed ID: 18976439
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
14. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T
Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral interferon-alpha gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation.
Hara H; Kobayashi A; Narumi K; Kondoh A; Yoshida K; Nishimoto T; Ohashi M; Higashihara E; Ohnami S; Yoshida T; Aoki K
Cancer Immunol Immunother; 2009 Jul; 58(7):1007-21. PubMed ID: 18998126
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease.
Natzke AM; Shaw JL; McKeller MR; Emo KL; Mullen CA
Biol Blood Marrow Transplant; 2007 Jan; 13(1):34-45. PubMed ID: 17222751
[TBL] [Abstract][Full Text] [Related]
17. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
18. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
Spaapen R; van den Oudenalder K; Ivanov R; Bloem A; Lokhorst H; Mutis T
Clin Cancer Res; 2007 Jul; 13(13):4009-15. PubMed ID: 17606735
[TBL] [Abstract][Full Text] [Related]
19. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
20. Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity.
Yang X; Chu Y; Wang Y; Zhang R; Xiong S
J Leukoc Biol; 2006 Dec; 80(6):1434-44. PubMed ID: 16980511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
